Daewoong Pharmaceutical Indonesia

Daewoong Pharmaceutical Indonesia is a prominent subsidiary of the South Korean pharmaceutical giant Daewoong Pharmaceutical, established to serve as a regional hub for Southeast Asia. The company operates through key entities including PT Daewoong Infion, a joint venture that launched Indonesia's first biologics manufacturing facility, and Daewoong Biologics Indonesia, which focuses on advanced regenerative medicine. Its commercial portfolio features high-growth products such as the erythropoietin biosimilar Epodion, the wound-healing agent Easyef, and the botulinum toxin Nabota. Daewoong is deeply integrated into the local healthcare ecosystem through its Open Collaboration strategy, which involves extensive partnerships with Indonesian universities and research institutes. The company's capabilities span from large-scale GMP biologics manufacturing to the development of innovative stem cell therapies.